In February 2023, I spoke with Dr. Allen Davidoff of XORTX Therapeutics Inc. (“XORTX”) about the company’s commitment to developing therapies for people living with progressive kidney disease. We…
Rare Community Profiles Rare Community Profiles is a new Patient Worthy article series of long-form interviews featuring various stakeholders in the rare disease community, such as patients, their families,…
In 2021, pain was defined as a core outcome for patients with autosomal dominant polycystic kidney disease (ADPKD). During the Polycystic Kidney Disease Regulatory Summit, researchers and patients alike discussed…
There are limited therapeutic options for people living with autosomal dominant polycystic kidney disease (ADPKD); currently, the only real standards-of-care include dialysis and kidney transplantation. When discussing the therapeutic landscape,…
Welcome to Study of the Week from Patient Worthy. In this segment, we select a study we posted about from the previous week that we think is of particular interest…
A few years ago, Dr. Thomas Weimbs, a researcher at the Weimbs Lab of UC Santa Barbara, performed a study on mice models of polycystic kidney disease (PKD). During…
Understanding how a patient's condition will progress is extremely important in providing them with the best treatment, and autosomal dominant polycystic kidney disease (ADPKD) does not stray from this trend.…
Happy Friday! This week, we'd like to get to know more about you! Fill out the 2021 Patient Worthy Reader's Survey and let us know the reasons you come to…
Welcome to Study of the Week from Patient Worthy. In this segment, we select a study we posted about from the previous week that we think is of particular interest…
According to a news article published by the Yale School of Medicine, Yale University researchers recently determined that autosomal dominant polycystic kidney disease (ADPKD) could potentially be reversed. Head researcher…
Acknowledgment: This story is sponsored by Otsuka America Pharmaceutical, Inc. and is promoted through the Patient Worthy Collaborative Content program. We only publish content that embodies our mission of providing relevant,…
Acknowledgment: This story is sponsored by Otsuka America Pharmaceutical, Inc. and is promoted through the Patient Worthy Collaborative Content program. We only publish content that embodies our mission of providing…
According to a story from GlobeNewswire, the biopharmaceutical company Reata Pharmaceuticals, Inc., recently announced that year two of its phase 3 clinical trial has been completed. This trial is testing…
In a recent press release, biopharmaceutical company Regulus Therapeutics, Inc. announced that their drug candidate, RGLS4326, received Orphan Drug Designation for the treatment of autosomal dominant polycystic kidney disease…
In 2015 families in Wales and England were given the good news that tolvaptan (JINARC®), which was developed for autosomal dominant polycystic kidney disease (ADPKD), will be available within one…
By Danielle Bradshaw from In The Cloud Copy Researchers in Germany have gone on record saying that there is a concern with how well patients are able to tolerate the…
By Rachel Whetstone from In The Cloud Copy Shelly Wheaton began a car sign campaign in September to look for a live kidney donor. She was on dialysis because…
According to a story from stltoday.com, the Saint Louis Walk for PKD (polycystic kidney disease) took place on Sunday, October 13th, 2019. This event was just one of many that…
If you or someone you know has ADPKD, email us at [email protected] We’d love to hear from you about your experience! According to a story from Medscape, a subject of…
Do you have ADPKD? If you or someone you know has ADPKD, email us at [email protected] We'd love to hear from you about your experience! According to a story from…
According to an article from PM360, Reata Pharmaceuticals has announced that its end-of-Phase 2 meeting with the Food and Drug Administration went according to plan. The American pharmaceutical company based…
According to a story from drugs.com, the biopharmaceutical company Reata Pharmaceuticals, Inc., recently announced that is had recently completed a end of Phase 2 meeting with officials from the US…
According to a story from thenewsreports.com, the biopharmaceutical company XORTX Therapeutics, Inc., recently announced that the company and its partner Cato Clinical Research have received correspondence from the US Food…
If you or someone you know has ADPKD, email us at [email protected] We'd love to hear from you about your experience! What is PKD and ADPKD? PKD (polycystic kidney disease)…
According to a story from businesswire.com, Otsuka Pharmaceutical Europe Ltd recently announced that its product JINARC, also known as tolvaptan, now has an expanded therapeutic indication after a recent approval…
© Copyright Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
